Tenax Therapeutics Announces European Patent Office Intention to Grant Patent for TNX-103

On September 16, 2025, Tenax Therapeutics, Inc. announced that the European Patent Office (EPO) has notified the company of its intention to grant a patent for TNX-103 (oral levosimendan) and other formulations of levosimendan, including its active metabolites. This patent will provide intellectual property protection for the use of these formulations in treating pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The press release detailing this announcement is attached as Exhibit 99.1. This development is significant for Tenax Therapeutics as it strengthens the company's intellectual property portfolio and supports its ongoing efforts in developing treatments for PH-HFpEF.